ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Naproxen

Also written as “PN400”, “naproxen” and “Naproxen Sodium (Aleve, BAY117031)”.

Its studies are mostly in Pain · Osteoarthritis · Migraine Disorders · Osteoarthritis, Knee · Pain, Postoperative, led by 12 companies.

Drug pageNaproxen: every studyMany companies study it; this page follows only the 65 they lead. All 150 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 15, 201065 company-led studies, 1 open or runningNext primary completion: Oct 29, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayerits history only240 open or runningphase 4since Apr 15, 2010Jun 5, 2008none ahead
Pfizerits history only80 open or runningphase 4since Mar 28, 2008Aug 17, 2006none ahead
GlaxoSmithKlineits history only70 open or runningphase 4since Nov 17, 2008Oct 14, 2005none ahead
Aralez Pharmaceuticalsits history only60 open or runningphase 3since Aug 18, 2006Aug 18, 2006none ahead
Johnson & Johnsonits history only50 open or runningphase 4since Dec 2, 2005Dec 2, 2005none ahead
Dr. Reddy's Laboratoriesits history only40 open or runningphase 1since Jan 8, 2010Jan 8, 2010none ahead
Merckits history only40 open or runningphase 4since Sep 7, 2005Sep 7, 2005none ahead
Ache Laboratorios Farmaceuticosits history only20 open or runningphase 3since Jul 7, 2011Jul 7, 2011none ahead
Perrigoits history only20 open or runningphase 1since Dec 5, 2008Dec 5, 2008none ahead
Amgenits history only10 open or runningphase 2since Oct 19, 2012Oct 19, 2012none ahead

Also a collaborator on its studies: Teva Pharmaceutical Industries and Pegus Research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Aug 17, 2006.

  1. Jan 12, 2018Phase 4 study in Pain, PostoperativeBayer · NCT03404206 · 387 enrolled · United States
  2. Feb 9, 2018Phase 4 study in DysmenorrheaBayer · NCT03448536 · 201 enrolled · United States
  3. Jun 18, 2018Phase 2 study in Osteoarthritis, KneeBayer · NCT03570554 · 41 enrolled · United States
  4. Oct 4, 2018Phase 1 study in HealthyJohnson & Johnson · NCT03697889 · 28 enrolled · Russian Federation
  5. Mar 1, 2019Phase 2 study in PainJohnson & Johnson · NCT03879408 · 290 enrolled · United States
  6. Oct 8, 2019Phase 2 study in Pain, PostoperativeBayer · NCT04132336 · 193 enrolled · United States
  7. Mar 5, 2020Phase 4 study in PainBayer · NCT04307940 · 221 enrolled · United States
  8. Jun 23, 2020Phase 2 study in PainJohnson & Johnson · NCT04447040 · 304 enrolled · United States
  9. Jul 12, 2021Phase 2 study in Soft Tissue InjuriesBayer · NCT05026320 · 76 enrolled · Germany
  10. Jul 28, 2022Phase 3 study in ToothacheBayer · NCT05485805 · 541 enrolled · United States
  11. Apr 25, 2023Phase 1 study in Orthodontic PainJohnson & Johnson · NCT05844995 · 24 enrolled · United States
  12. May 10, 2024Phase 1 study in PainBayer · NCT06415019 · 236 enrolled · United States
  13. Jul 11, 2024Phase 1 study in PainBayer · NCT06511973 · 42 enrolled · United States
  14. Oct 15, 2026Kenvue Brands’ first study: phase 3 study in FeverNew to Kenvue BrandsKenvue Brands · NCT07948811 · 292 planned · United States

Ahead

  1. Oct 29, 2027Primary completion: phase 3 study in FeverKenvue Brands · NCT07948811

TargetBeta

PTGS1 →PTGS2 →read by rule
“Cyclooxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4137
IbuprofenrulePfizerphase 4113
AspirinruleBayerphase 484
dexketoprofenruleMenarini Groupphase 48
SulfasalazineruleBristol-Myers Squibbphase 47
dexibuprofenruleaponia-laboratories-incphase 46
BenzydamineruleAngelini Pharmaphase 44
DipyroneruleHypera Pharmaphase 44
PiroxicamruleTaisho Pharmaceuticalphase 44
FlurbiprofenruleGlaxoSmithKlinephase 312

Studies

The newest 60 of 65 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07948811Fever · United States3RecruitingKenvue BrandsOct 29, 2027292
NCT06511973Pain · United States1CompletedBayerAug 20, 202442
NCT06415019Pain · United States1CompletedBayerAug 1, 2024236
NCT05844995Orthodontic Pain · United States1CompletedJohnson & JohnsonFeb 12, 202424
NCT05485805Toothache · United States3CompletedBayerJan 25, 2024541
NCT05026320Soft Tissue Injuries · Germany2CompletedBayerDec 20, 202176
NCT04447040Pain · United States2CompletedJohnson & JohnsonApr 9, 2021304
NCT04307940Pain · United States4CompletedBayerOct 2, 2020221
NCT04132336Pain, Postoperative · United States2CompletedBayerMar 2, 2020193
NCT03879408Pain · United States2CompletedJohnson & JohnsonNov 7, 2019290
NCT03697889Healthy · Russian Federation1CompletedJohnson & JohnsonDec 17, 201828
NCT03570554Osteoarthritis, Knee · United States2CompletedBayerJun 14, 201941
NCT03448536Dysmenorrhea · United States4CompletedBayerSep 5, 2018201
NCT03404206Pain, Postoperative · United States4CompletedBayerJul 6, 2018387
NCT02549469Pain1CompletedBayerMay 200732
NCT02229461Hematology · United States1CompletedBayerMay 2015117
NCT01726920Migraine Disorders3WithdrawnAche Laboratorios FarmaceuticosDec 20140
NCT01712009Breast Neoplasms · United States2CompletedAmgenMar 18, 2015600
NCT01557816Osteoarthritis, Knee · United States–UNKNOWNAnalgesic SolutionsJun 201270
NCT01495858Pain, Postoperative · United States3CompletedBayerFeb 2012267
NCT01427803Pain · United States3CompletedBayerDec 2011778
NCT01390324Migraine Disorders3WithdrawnAche Laboratorios FarmaceuticosMar 20120
NCT01389284Pain, Postoperative · United States3CompletedBayerSep 2011300
NCT01383486Pain · United States3CompletedBayerAug 2011253
NCT01365052Pain · United States3CompletedBayerJul 2011326
NCT01280591Pain, Postoperative · United States3CompletedBayerJan 2011712
NCT01231490Osteoarthritis · United Kingdom2CompletedGlaxoSmithKlineJan 200953
NCT01131767Healthy · India1CompletedDr. Reddy's LaboratoriesAug 200426
NCT01131728Healthy · India1CompletedDr. Reddy's LaboratoriesAug 200426
NCT01118273Sleep · United States4CompletedBayerFeb 2008162
NCT01102660Osteoarthritis · United States2CompletedPfizerFeb 2011172
NCT01052792Healthy · India1CompletedDr. Reddy's LaboratoriesMay 200626
NCT01052129Healthy · India1CompletedDr. Reddy's LaboratoriesMay 200626
NCT00969449Pharmacokinetics · United States1CompletedBayerMay 200928
NCT00844805Spondylitis, Ankylosing3CompletedMerckApr 2011158
NCT00843024Migraine Disorders · United States3CompletedGlaxoSmithKlineMay 2010589
NCT00830050Osteoarthritis · United KingdomEarly 1CompletedPfizerDec 201024
NCT00818415Pain · United States1CompletedBayerNov 200832
NCT00804401Bioequivalency1CompletedPerrigoJul 200434
NCT00803764Bioequivalency1CompletedPerrigoJul 200434
NCT00792636Migraine Disorders · United States4CompletedGlaxoSmithKlineNov 2009407
NCT00772967Osteoarthritis1CompletedMerckNov 200822
NCT00751556Healthy · United States1CompletedBayerMar 200832
NCT00751400Pain · United States3CompletedBayerNov 2008497
NCT00743587Osteoarthritis Thumbs · Belgium1CompletedPfizerMar 200936
NCT00720057Toothache · United States3CompletedBayerAug 2008312
NCT00692016Bioavailability · United States1CompletedBayerFeb 200832
NCT00692055Arthritis · United States1CompletedAralez PharmaceuticalsJul 200830
NCT00676442Arthritis · United States1CompletedAralez PharmaceuticalsJun 200824
NCT00665743Arthritis · United States1CompletedAralez PharmaceuticalsJun 200830
NCT00652808Osteoarthritis · Korea, Republic of3CompletedPfizer265
NCT00650455Arthritis, Rheumatoid · United States, Canada4CompletedPfizerJan 2005489
NCT00648258Osteoarthritis · Taiwan3CompletedPfizer130
NCT00601458Acute Pain1CompletedMerckJan 2008100
NCT00599404Healthy1CompletedAralez PharmaceuticalsFeb 200818
NCT00442221Migraine Disorders · United States3CompletedAralez Pharmaceuticals500
NCT00392080Osteoarthritis · United States1CompletedPfizer340
NCT00387881Migraine without Aura · United States3CompletedGlaxoSmithKlineFeb 2008679
NCT00367211Osteoarthritis · United States3CompletedAralez PharmaceuticalsSep 2007400
NCT00366262Healthy · United States1CompletedPfizer

How it is read

Names in the registry

  • “Naproxen”, 17 entries
  • “PN400”, 8 entries
  • “naproxen”, 5 entries
  • “Naproxen Sodium (Aleve, BAY117031)”, 4 entries
  • “Naproxen Sodium ER (BAYH6689)”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.